The role of the interactions between tumor cells and their microenvironment (TME) is now well-established in various stages of cancer development. Cytokines, produced by both the cancer and the immune cells, actively contribute to these critical connections (see the previous posts related to the crosstalk between cancer and immune cells in relation to tumor escape, immunoediting and immunosurveillance).
In a recent review published in BBA, RayBiotech‘s team highlights the “cytokine signatures and dynamics” seen during cancer development. They also demonstrate the necessity of designing relevant multiplex immunoassays for the profiling and the quantification of cytokines in biomarker and anti-cancer drug discovery programs.
Source:
Valerie Sloane Jones, Ren-Yu Huang, Li-Pai Chen, Zhe-Sheng Chen, Liwu Fu, Ruo-Pan Huang “Cytokines in cancer drug resistance: Cues to new therapeutic strategies” (2016) Biochimica et Biophysica Acta, Volume 1865, Issue 2, 255–265. DOI:10.1016/j.bbcan.2016.03.005.
Download the publication written by RayBiotech, the leader in planar Antibody Arrays.
